W. Marston Linehan, M.D.
Urologic Oncology Branch
National Cancer Institute
9000 Rockville Pike
Building 10, MSC 1501 Room 10-2B47
Bethesda, MD 20892
Dr. Linehan came to the National Institutes of Health (NIH) after completing his training in urologic surgery at Duke University Medical Center in Durham, N.C. He has held positions of increasing responsibility at the National Cancer Institute (NCI) and was part of the team responsible for identification of the von Hippel-Lindau (VHL) and hereditary papillary renal cell carcinoma (HPRC) kidney cancer genes. He has a wide range of scientific interests and accomplishments spanning molecular genetics of urologic malignancies and evaluation and treatment of patients with hereditary and sporadic forms of genitourinary cancers.
Dr. Linehan's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with kidney cancer, Birt-Hogg-Dube, leiomyomatosis, von Hippel-Lindau, or solid tumors. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.